busulfan

Summary

Summary: An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

Top Publications

  1. Zwaveling J, Press R, Bredius R, van Derstraaten T, Den Hartigh J, Bartelink I, et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit. 2008;30:504-10 pubmed publisher
    High busulfan exposure is associated with increased toxicity, for example veno-occlusive disease, whereas low exposure results in less efficacy such as lower engraftment rates...
  2. Nath C, Shaw P. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol. 2007;2:75-91 pubmed
    ..Only when this target is defined will therapeutic drug monitoring be useful to minimise toxicity, maximise efficacy and improve transplant outcome...
  3. Shah A. Successful pregnancy after busulfan/cytoxan conditioning regimen for AML. J Pediatr Hematol Oncol. 2011;33:e180-1 pubmed publisher
    ..In this case report we report the case of a 27 year-old female who had a normal full term delivery 19 years following a myeloablative autologous transplant for relapsed acute myelogenous leukemia...
  4. Choi B, Chun E, Kim M, Kim S, Yoon K, Lee K, et al. Human B cell development and antibody production in humanized NOD/SCID/IL-2R?(null) (NSG) mice conditioned by busulfan. J Clin Immunol. 2011;31:253-64 pubmed publisher
    b>Busulfan treatment as a chemotherapeutic agent has been considered an alternative approach in xenograft model because it offers a simple, convenient, effective, and less toxic conditioning regimen.
  5. Kim S, Lee J, Hur E, Lee J, Kim D, Lim S, et al. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1222-30 pubmed publisher
    Intravenous (i.v.) busulfan can produce a more consistent pharmacokinetic profile than oral formulations can, but nonetheless, significant interpatient variability is evident...
  6. Gaziev J, Nguyen L, Puozzo C, Mozzi A, Casella M, Perrone Donnorso M, et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood. 2010;115:4597-604 pubmed publisher
    We prospectively studied the pharmacokinetics (PK) and clinical outcomes of intravenous busulfan (Bu) in 71 children with preexisting liver damage who underwent hematopoietic stem cell transplantation for thalassemia...
  7. Dean R, Pohlman B, Sweetenham J, Sobecks R, Kalaycio M, Smith S, et al. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br J Haematol. 2010;148:226-34 pubmed publisher
    Autologous stem cell transplantation (ASCT) with cyclophosphamide, etoposide and oral busulfan (BuCyVP) is an effective therapy for relapsed or refractory non-Hodgkin lymphoma (NHL)...
  8. Gupta T, Kannan S, Dantkale V, Laskar S. Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2011;4:17-29 pubmed
    Cyclophosphamide plus total body irradiation (CYTBI) and oral busulfan plus cyclophosphamide (BUCY) are commonly used conditioning regimens prior to allogeneic hematopoietic stem cell transplantation (HSCT) in patients with leukemia...
  9. McCune J, Holmberg L. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol. 2009;5:957-69 pubmed publisher
    ..v.) busulfan, therapeutic drug monitoring and clinical outcome in hematopoietic stem cell transplant (HCT) patients...

More Information

Publications62

  1. Molyneux G, Andrews M, Sones W, York M, Barnett A, Quirk E, et al. Haemotoxicity of busulphan, doxorubicin, cisplatin and cyclophosphamide in the female BALB/c mouse using a brief regimen of drug administration. Cell Biol Toxicol. 2011;27:13-40 pubmed publisher
  2. Zhang H, Graiser M, Hutcherson D, Dada M, McMillan S, Ali Z, et al. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1287-94 pubmed publisher
    The clinical advantage of pharmacokinetic (PK)-directed-based dosing on intravenous (i.v.) versus oral busulfan-related toxicity and survival remains unclear...
  3. Versace F, Uppugunduri C, Krajinovic M, Theoret Y, Gumy Pause F, Mangin P, et al. A novel method for quantification of sulfolane (a metabolite of busulfan) in plasma by gas chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2012;404:1831-8 pubmed publisher
    The role of busulfan (Bu) metabolites in the adverse events seen during hematopoietic stem cell transplantation and in drug interactions is not explored...
  4. Xie J, Larochelle A, Maric I, Faulhaber M, Donahue R, Dunbar C. Repetitive busulfan administration after hematopoietic stem cell gene therapy associated with a dominant HDAC7 clone in a nonhuman primate. Hum Gene Ther. 2010;21:695-703 pubmed publisher
    ..We administered four monthly busulfan (Bu) infusions to induce hematopoietic stress in a healthy rhesus macaque previously transplanted with CD34+ ..
  5. Takamatsu Y, Sasaki N, Ogata K, Yukawa E, Jimi S, Hara S, et al. Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation. Cancer Chemother Pharmacol. 2010;65:1203-7 pubmed publisher
    The aim of this study is to determine the population pharmacokinetics of oral busulfan in Japanese adults.
  6. Perez Crespo M, Pericuesta E, Pérez Cerezales S, Arenas M, Lobo M, Díaz Gil J, et al. Effect of liver growth factor on both testicular regeneration and recovery of spermatogenesis in busulfan-treated mice. Reprod Biol Endocrinol. 2011;9:21 pubmed publisher
    ..Liver growth factor (LGF) is a biliprotein with hepatic mitogen activity. Its concentration increases markedly in the presence of any type of liver injury, and it shows in vivo therapeutic biological activity at extrahepatic sites...
  7. Juenke J, Miller K, McMillin G, Johnson Davis K. An automated method for supporting busulfan therapeutic drug monitoring. Ther Drug Monit. 2011;33:315-20 pubmed publisher
    b>Busulfan is a chemotherapeutic agent commonly used for myeloablative conditioning regimens such as in the treatment of chronic myelogenous leukemia...
  8. Hassan M, Andersson B. Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. Pharmacogenomics. 2013;14:75-87 pubmed publisher
    ..b>Busulfan (Bu) and cyclophosphamide (Cy) are the most commonly used alkylators in high-dose pretransplant conditioning for ..
  9. Nguyen L. Integration of modelling and simulation into the development of intravenous busulfan in paediatrics: an industrial experience. Fundam Clin Pharmacol. 2008;22:599-604 pubmed publisher
    b>Busulfan (Bu) is commonly used in preparative conditioning regimen prior to bone marrow transplantation in infants (< 1 year old), children and adolescents (up to 17 years old)...
  10. Saito B, Fukuda T, Yokoyama H, Kurosawa S, Takahashi T, Fuji S, et al. Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen. Biol Blood Marrow Transplant. 2008;14:1148-1155 pubmed publisher
    ..and little information is available on the clinical impact of chimerism status in patients conditioned with a busulfan-containing regimen...
  11. Abbasi N, Vadnais B, Knutson J, Blough D, Kelly E, O Donnell P, et al. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J Clin Pharmacol. 2011;51:1429-38 pubmed publisher
    ..is often conducted in hematopoietic cell transplant (HCT) patients conditioned with intravenous (IV) or oral busulfan to lower rates of rejection, nonrelapse mortality, and relapse...
  12. Kang B, Kim W, Kim C, Jang G, Lee S, Choi Y, et al. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Invest New Drugs. 2010;28:516-22 pubmed publisher
    ..the efficacy and safety of yttrium-90-ibritumomab tiuxetan ((90)Y-ibritumomab) combined with intravenous busulfan, cyclophosphamide, and etoposide (Bu/Cy/E) followed by ASCT in patients with relapsed or refractory B-cell non-..
  13. Chalati T, Horcajada P, Couvreur P, Serre C, Ben Yahia M, Maurin G, et al. Porous metal organic framework nanoparticles to address the challenges related to busulfan encapsulation. Nanomedicine (Lond). 2011;6:1683-95 pubmed publisher
    b>Busulfan is an alkylating agent widely used in chemotherapy, but with severe side effects...
  14. Chiesa R, Cappelli B, Crocchiolo R, Frugnoli I, Biral E, Noè A, et al. Unpredictability of intravenous busulfan pharmacokinetics in children undergoing hematopoietic stem cell transplantation for advanced beta thalassemia: limited toxicity with a dose-adjustment policy. Biol Blood Marrow Transplant. 2010;16:622-8 pubmed publisher
    ..Oral Busulfan (Bu) based conditioning is widely used in this setting...
  15. Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquieres H, et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica. 2012;97:1751-6 pubmed publisher
  16. Wilkinson F, Sergijenko A, Langford Smith K, Malinowska M, Wynn R, Bigger B. Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation. Mol Ther. 2013;21:868-76 pubmed publisher
    ..We compared hematopoietic donor cell brain engraftment after bone marrow (BM) transplants in busulfan- or irradiation-conditioned mice...
  17. Sadeghi B, Aghdami N, Hassan Z, Forouzanfar M, Rozell B, Abedi Valugerdi M, et al. GVHD after chemotherapy conditioning in allogeneic transplanted mice. Bone Marrow Transplant. 2008;42:807-18 pubmed publisher
    ..We report a mouse model of GVHD using BU-CY conditioning that represents the most common myeloablative-conditioning regimen in clinical SCT. This model can be utilized to study the role of conditioning on mechanisms underlying GVHD...
  18. Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, et al. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood. 2011;118:4258-64 pubmed publisher
    ..To improve the antitumor activity of conditioning, we combined clofarabine with myeloablative doses of busulfan in a phase 1/2 study in nonremission hematologic malignancies...
  19. Snyder M, Ritchie J. Quantification of busulfan in plasma using liquid chromatography electrospray tandem mass spectrometry (HPLC-ESI-MS/MS). Methods Mol Biol. 2010;603:129-36 pubmed publisher
    b>Busulfan is a chemotherapy drug widely used as part of conditioning regimens for patients undergoing bone marrow transplantation (BMT)...
  20. Al Hashmi S, Hassan Z, Sadeghi B, Rozell B, Hassan M. Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen. Int J Clin Exp Pathol. 2011;4:596-605 pubmed
    ..This is the first study describing early histopathological changes after conditioning regimen with busulphan/cyclophosphamide and dynamics of GVHD development in several major internal organs...
  21. Andersson B, Valdez B, de Lima M, Wang X, Thall P, Worth L, et al. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. 2011;17:893-900 pubmed publisher
    Although a combination of i.v. busulfan (Bu) and fludarabine (Flu) is a safe, reduced-toxicity conditioning program for acute myelogenous leukemia/myelodysplastic syndromes (AML/MDS), recurrent leukemia posttransplantation remains a ..
  22. Cho W, Lee J, Chung N, Jung M, Cho B, Suh B, et al. Primary ovarian dysfunction after hematopoietic stem cell transplantation during childhood: busulfan-based conditioning is a major concern. J Pediatr Endocrinol Metab. 2011;24:1031-5 pubmed
    ..As preparative regimens for HSCT, 23 patients received total body irradiation (TBI)-based regimen, 19 received busulfan (BU)-based regimen, 4 received both BU- and TBI-based, and 4 received reduced intensity conditioning regimen...
  23. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, et al. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012;18:1677-86 pubmed publisher
    We developed a new high-dose combination of infusional gemcitabine with busulfan and melphalan for lymphoid tumors...
  24. Lewis C, Manning J, Barr C, Peake K, Humphries R, Rossi F, et al. Myelosuppressive conditioning using busulfan enables bone marrow cell accumulation in the spinal cord of a mouse model of amyotrophic lateral sclerosis. PLoS ONE. 2013;8:e60661 pubmed publisher
    ..mice that over-express human mutant superoxide dismutase 1, a model of amyotrophic lateral sclerosis, with busulfan to determine whether this commonly used chemotherapeutic leads to stable chimerism and promotes the entry of bone ..
  25. Russell J, Duan Q, Chaudhry M, Savoie M, Balogh A, Turner A, et al. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biol Blood Marrow Transplant. 2008;14:888-95 pubmed publisher
    ..sibling donors (MSD) after myeloablative conditioning including fludarabine (Flu) and once-daily intravenous busulfan (Bu)...
  26. Lee J, Kang H, Lee S, Yu K, Kim N, Yuk Y, et al. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Biol Blood Marrow Transplant. 2012;18:944-50 pubmed publisher
    b>Busulfan has a narrow therapeutic range, and in children, pharmacokinetic variability has been found to be high even after the use of intravenous (i.v.) busulfan...
  27. Molina B, Alonso L, Gonzalez Vicent M, Andion M, Hernandez C, Lassaletta A, et al. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients. Pediatr Hematol Oncol. 2011;28:115-23 pubmed publisher
    ..The conditioning regimen used in all cases consisted of high-dose of busulfan and melphalan. Median age at transplantation was 3 years (range: 0.7-14 years)...
  28. Ohira T, Ando R, Okada Y, Suzuki H, Saito T, Nakazawa T, et al. Sequence of busulfan-induced neural progenitor cell damage in the fetal rat brain. Exp Toxicol Pathol. 2013;65:523-30 pubmed publisher
    The sequence of neural progenitor cell (NPC) damage induced in fetal rat brain by transplacental exposure to busulfan, an antineoplastic bifunctional-alkylating agent, on gestational day 13 was examined by immunohistochemical and real-..
  29. Ansari M, Uppugunduri C, Déglon J, Theoret Y, Versace F, Gumy Pause F, et al. A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2012;26:1437-46 pubmed publisher
    b>Busulfan (Bu) is an important component of the myeloablative conditioning regimen prior to hematopoietic stem cell transplantation (HSCT) especially in children...
  30. Hayakawa J, Hsieh M, Uchida N, Phang O, Tisdale J. Busulfan produces efficient human cell engraftment in NOD/LtSz-Scid IL2Rgamma(null) mice. Stem Cells. 2009;27:175-82 pubmed publisher
    ..In this work, we examined the use of parenteral busulfan as an alternative conditioning agent...
  31. Andion M, Molina B, Gonzalez Vicent M, Alonso L, Hernandez C, Lassaletta A, et al. High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study. J Pediatr Hematol Oncol. 2011;33:e89-91 pubmed publisher
    ..The conditioning regimen used in all patients consisted of busulfan and cyclophosphamide. Median age was 6 years (range 2 to 16 y)...
  32. Pidala J, Kim J, Anasetti C, Kharfan Dabaja M, Nishihori T, Field T, et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol. 2010;3:36 pubmed publisher
    ..We retrospectively compared outcomes of a consecutive series of 51 AML patients treated with oral busulfan (1 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 mg/kg IV × 2 days) - (Bu/Cy) with 100 consecutive ..
  33. Espejel S, Romero R, Alvarez Buylla A. Radiation damage increases Purkinje neuron heterokaryons in neonatal cerebellum. Ann Neurol. 2009;66:100-9 pubmed publisher
    ..Here we investigated whether radiation plays a role in the formation of Purkinje neuron heterokaryons...
  34. Ciurea S, Andersson B. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:523-36 pubmed publisher
    The development of intravenous busulfan (Bu) and its incorporation in the preparative regimens for allogeneic stem cell transplantation has changed transplantation for myelogenous malignancies...
  35. Copelan E, Hamilton B, Avalos B, Ahn K, Bolwell B, Zhu X, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013;122:3863-70 pubmed publisher
    Cyclophosphamide combined with total body irradiation (Cy/TBI) or busulfan (BuCy) are the most widely used myeloablative conditioning regimens for allotransplants. Recent data regarding their comparative effectiveness are lacking...
  36. Savas Erdeve S, Berberoglu M, Siklar Z, Hacihamdioglu B, Ocal G, Ertem M, et al. Primary adrenal insufficiency in a child after busulfan and cyclophosphamide-based conditioning for hematopoietic stem cell transplantation. J Pediatr Endocrinol Metab. 2011;24:853-5 pubmed
    ..secondary adrenal insufficiency has been diagnosed, no primary adrenal insufficiency has been reported after busulfan and cyclophosphamide (Bu/Cy)-based conditioning regimens for stem cell transplantation in children...
  37. Johnson L, Orchard P, Baker K, Brundage R, Cao Q, Wang X, et al. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol. 2008;48:1052-62 pubmed publisher
    The effect of glutathione S-transferase variants on pediatric busulfan metabolism was investigated by noncompartmental and population pharmacokinetic modeling...
  38. Enquist I, Nilsson E, Mansson J, Ehinger M, Richter J, Karlsson S. Successful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher disease. Stem Cells. 2009;27:744-52 pubmed publisher
    ..Moreover, we applied nonmyeloablative doses of busulfan as a pretransplant conditioning regimen and show that even WT cell engraftment in the range of 1%-10% can confer ..
  39. Paci A, Vassal G, Moshous D, Dalle J, Bleyzac N, Neven B, et al. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. Ther Drug Monit. 2012;34:198-208 pubmed publisher
    Intravenous (IV) busulfan (Bu) dosing approved in Europe based on 5 body weight (BW) strata has been validated for targeting Bu exposures in children undergoing hematopoietic stem-cell transplantation and with mostly malignant diseases...
  40. Tagirov M, Golovan S. The effect of busulfan treatment on endogenous spermatogonial stem cells in immature roosters. Poult Sci. 2012;91:1680-5 pubmed publisher
    ..Currently the chemical treatment with alkylating agent busulfan is the method of choice in mammals...
  41. Law J, Cowan M, Dvorak C, Musick L, Long Boyle J, Baxter Lowe L, et al. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biol Blood Marrow Transplant. 2012;18:1656-63 pubmed publisher
    ..We previously reported that targeted i.v. busulfan, fludarabine, and rabbit anti-thymocyte globulin (rATG) decreased toxicity but had a graft failure rate of 21%...
  42. Courtney J, Harney R, Li Y, Lundell G, McMillin G, Agarwal G, et al. Determination of busulfan in human plasma using an ELISA format. Ther Drug Monit. 2009;31:489-94 pubmed publisher
    High-dose busulfan is an important component of many bone marrow transplantation-preparative regimens...
  43. Bredeson C, Zhang M, Agovi M, Bacigalupo A, Bahlis N, Ballen K, et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:993-1003 pubmed publisher
    ..regimen using low-dose rabbit antithymocyte globulin (ATG; Thymoglobulin [TG]) with fludarabine and intravenous busulfan (FluBuTG)...
  44. Sakurada Y, Kudo S, Iwasaki S, Miyata Y, Nishi M, Masumoto Y. Collaborative work on evaluation of ovarian toxicity. 5) Two- or four-week repeated-dose studies and fertility study of busulfan in female rats. J Toxicol Sci. 2009;34 Suppl 1:SP65-72 pubmed
    b>Busulfan, an antineoplastic agent that targets small follicles (primordial and primary follicles), was given orally to female Sprague-Dawley rats (0, 0.1, 0.5, or 1...
  45. Majhail N, Brazauskas R, Rizzo J, Sobecks R, Wang Z, Horowitz M, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011;117:316-22 pubmed publisher
    ..We evaluated the incidence and risk factors for solid cancers after HCT using high-dose busulfan-cyclophosphamide conditioning in 4318 recipients of first allogeneic HCT for acute myeloid leukemia in first ..
  46. Abe T, Masuda S, Tanaka Y, Nitta S, Kitano Y, Hayashi S, et al. Maternal administration of busulfan before in utero transplantation of human hematopoietic stem cells enhances engraftments in sheep. Exp Hematol. 2012;40:436-44 pubmed publisher
    ..b>Busulfan (BU), a myeloablative agent, is often administered to patients before hematopoietic stem cells transplantation to ..
  47. Zohni K, Zhang X, Tan S, Chan P, Nagano M. The efficiency of male fertility restoration is dependent on the recovery kinetics of spermatogonial stem cells after cytotoxic treatment with busulfan in mice. Hum Reprod. 2012;27:44-53 pubmed publisher
    ..It has not been well documented, however, whether the recovery of SSC population size after cytotoxic damage associates with the kinetics of male fertility restoration. We addressed this issue using the mouse as a model...
  48. Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynae. Gynecol Oncol. 2009;114:199-205 pubmed publisher
    ..Therefore, we started a prospectively randomized phase III trial comparing these two drugs in early recurrent ovarian cancer...
  49. Danylesko I, Shimoni A, Nagler A. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike. Bone Marrow Transplant. 2012;47:5-14 pubmed publisher
    ..Promising results were seen in myelodysplastic syndrome (survival 36-70%) and leukemia in remission (60-70%). Randomized prospective studies will be needed to better define the role of treosulfan-based regimens in SCT...
  50. Haddad E, Leroy S, Buckley R. B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?. J Allergy Clin Immunol. 2013;131:994-1000 pubmed publisher
    ..analysis of B-cell function in published reports and showed that only a conditioning regimen that contained busulfan was significantly associated with better B-cell function after transplantation...
  51. Pielichowski W, Gawronski K, Mlot B, Oborska S, Waśko Grabowska A, Rzepecki P. Triple drug combination in the prevention of nausea and vomiting following busulfan plus cyclophosphamide chemotherapy before allogeneic hematopoietic stem cell transplantation. J BUON. 2011;16:541-6 pubmed
  52. Lampron A, Lessard M, Rivest S. Effects of myeloablation, peripheral chimerism, and whole-body irradiation on the entry of bone marrow-derived cells into the brain. Cell Transplant. 2012;21:1149-59 pubmed publisher
    ..We conclude that myeloablation, damages to the brain integrity, or the BBB and peripheral chimerism are not responsible for the entry of BMDCs into the CNS following irradiation...
  53. Lee J, Joo Y, Kim H, Ryoo H, Kim M, Lee G, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013;31:701-9 pubmed publisher
    ..We conducted a phase III randomized clinical trial to compare two myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (HCT) in patients with leukemia and myelodysplastic syndrome...